Nestlé completes acquisition of Aimmune Therapeutics

[Swissallergy]

Aimmune’s PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally.”” said Greg Behar, CEO of NHSc. Nestlé announce the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc’s global pharmaceutical business.

Acquisition of Aimmune Therapeutics marks an important milestone:
“”Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support healthier lives,” The development program for Aimmune — which consists of the potential use of PALFORZIA in toddlers and adults, multiple clinical development programs in other allergies, and the development of the monoclonal antibody AlMab7195 — will proceed as planned. Read Press Release”

[Auteur]

Messages